For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity

For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity

Intratumoral immunotherapy can potentially modulate the tumor microenvironment (TME) and potentiate the effects of concomitant or sequential systemic immunotherapies. Intratumoral administration of different Toll-like receptor agonists, including TLR4, can potentiate these effects through innate and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical cancer research 2019-02, Vol.25 (4), p.1127-1129
Hauptverfasser: Marquez-Rodas, Ivan, Aznar, María Angela, Calles, Antonio, Melero, Ignacio
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1129
container_issue 4
container_start_page 1127
container_title Clinical cancer research
container_volume 25
creator Marquez-Rodas, Ivan
Aznar, María Angela
Calles, Antonio
Melero, Ignacio
description Intratumoral immunotherapy can potentially modulate the tumor microenvironment (TME) and potentiate the effects of concomitant or sequential systemic immunotherapies. Intratumoral administration of different Toll-like receptor agonists, including TLR4, can potentiate these effects through innate and adaptive immunity connection.See related article by Bhatia et al., p. 1185.
doi_str_mv 10.1158/1078-0432.CCR-18-2690
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2114695509</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2114695509</sourcerecordid><originalsourceid>FETCH-LOGICAL-c309t-2b5dcbc905336336730ab1fa316f669e4297971526f87d8716e95833265abe233</originalsourceid><addsrcrecordid>eNo9kFFLwzAQx4Mobk4_gpJHXzpzSZM2TzKK08FAGBMfQ9qmrNq0M0mFfXtbtgkHd9z9747_D6F7IHMAnj4BSdKIxIzOs2wTQRpRIckFmgLnScSo4JdDfdZM0I33X4RADCS-RhNGqKCciCnaLDuHP3edxWFncGaaBm-7pvHPeNUGp0NvO6eHnjM6WNMGvK7bbz8MWx0M1m2JF6Xeh_rX4JW1fVuHwy26qnTjzd0pz9DH8mWbvUXr99dVtlhHBSMyRDTnZZEXknDGxBAJIzqHSjMQlRDSxFQmMgFORZUmZZqAMJKnbLSmc0MZm6HH4929635644OytS8GB7o1Xe8VBYiF5JzIQcqP0sJ13jtTqb2rrXYHBUSNONWISo2o1IBTQapGnMPew-lFn1tT_m-d-bE_fS5uug</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2114695509</pqid></control><display><type>article</type><title>For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity</title><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Marquez-Rodas, Ivan ; Aznar, María Angela ; Calles, Antonio ; Melero, Ignacio</creator><creatorcontrib>Marquez-Rodas, Ivan ; Aznar, María Angela ; Calles, Antonio ; Melero, Ignacio</creatorcontrib><description>Intratumoral immunotherapy can potentially modulate the tumor microenvironment (TME) and potentiate the effects of concomitant or sequential systemic immunotherapies. Intratumoral administration of different Toll-like receptor agonists, including TLR4, can potentiate these effects through innate and adaptive immunity connection.See related article by Bhatia et al., p. 1185.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-18-2690</identifier><identifier>PMID: 30262506</identifier><language>eng</language><publisher>United States</publisher><ispartof>Clinical cancer research, 2019-02, Vol.25 (4), p.1127-1129</ispartof><rights>2018 American Association for Cancer Research.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c309t-2b5dcbc905336336730ab1fa316f669e4297971526f87d8716e95833265abe233</citedby><cites>FETCH-LOGICAL-c309t-2b5dcbc905336336730ab1fa316f669e4297971526f87d8716e95833265abe233</cites><orcidid>0000-0002-2547-1947</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30262506$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Marquez-Rodas, Ivan</creatorcontrib><creatorcontrib>Aznar, María Angela</creatorcontrib><creatorcontrib>Calles, Antonio</creatorcontrib><creatorcontrib>Melero, Ignacio</creatorcontrib><title>For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Intratumoral immunotherapy can potentially modulate the tumor microenvironment (TME) and potentiate the effects of concomitant or sequential systemic immunotherapies. Intratumoral administration of different Toll-like receptor agonists, including TLR4, can potentiate these effects through innate and adaptive immunity connection.See related article by Bhatia et al., p. 1185.</description><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNo9kFFLwzAQx4Mobk4_gpJHXzpzSZM2TzKK08FAGBMfQ9qmrNq0M0mFfXtbtgkHd9z9747_D6F7IHMAnj4BSdKIxIzOs2wTQRpRIckFmgLnScSo4JdDfdZM0I33X4RADCS-RhNGqKCciCnaLDuHP3edxWFncGaaBm-7pvHPeNUGp0NvO6eHnjM6WNMGvK7bbz8MWx0M1m2JF6Xeh_rX4JW1fVuHwy26qnTjzd0pz9DH8mWbvUXr99dVtlhHBSMyRDTnZZEXknDGxBAJIzqHSjMQlRDSxFQmMgFORZUmZZqAMJKnbLSmc0MZm6HH4929635644OytS8GB7o1Xe8VBYiF5JzIQcqP0sJ13jtTqb2rrXYHBUSNONWISo2o1IBTQapGnMPew-lFn1tT_m-d-bE_fS5uug</recordid><startdate>20190215</startdate><enddate>20190215</enddate><creator>Marquez-Rodas, Ivan</creator><creator>Aznar, María Angela</creator><creator>Calles, Antonio</creator><creator>Melero, Ignacio</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2547-1947</orcidid></search><sort><creationdate>20190215</creationdate><title>For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity</title><author>Marquez-Rodas, Ivan ; Aznar, María Angela ; Calles, Antonio ; Melero, Ignacio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c309t-2b5dcbc905336336730ab1fa316f669e4297971526f87d8716e95833265abe233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marquez-Rodas, Ivan</creatorcontrib><creatorcontrib>Aznar, María Angela</creatorcontrib><creatorcontrib>Calles, Antonio</creatorcontrib><creatorcontrib>Melero, Ignacio</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marquez-Rodas, Ivan</au><au>Aznar, María Angela</au><au>Calles, Antonio</au><au>Melero, Ignacio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2019-02-15</date><risdate>2019</risdate><volume>25</volume><issue>4</issue><spage>1127</spage><epage>1129</epage><pages>1127-1129</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Intratumoral immunotherapy can potentially modulate the tumor microenvironment (TME) and potentiate the effects of concomitant or sequential systemic immunotherapies. Intratumoral administration of different Toll-like receptor agonists, including TLR4, can potentiate these effects through innate and adaptive immunity connection.See related article by Bhatia et al., p. 1185.</abstract><cop>United States</cop><pmid>30262506</pmid><doi>10.1158/1078-0432.CCR-18-2690</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-2547-1947</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1078-0432
ispartof Clinical cancer research, 2019-02, Vol.25 (4), p.1127-1129
issn 1078-0432
1557-3265
language eng
recordid cdi_proquest_miscellaneous_2114695509
source American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
title For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T00%3A48%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=For%20Whom%20the%20Cell%20Tolls?%20Intratumoral%20Treatment%20Links%20Innate%20and%20Adaptive%20Immunity&rft.jtitle=Clinical%20cancer%20research&rft.au=Marquez-Rodas,%20Ivan&rft.date=2019-02-15&rft.volume=25&rft.issue=4&rft.spage=1127&rft.epage=1129&rft.pages=1127-1129&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-18-2690&rft_dat=%3Cproquest_cross%3E2114695509%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2114695509&rft_id=info:pmid/30262506&rfr_iscdi=true